Biotech News
Related news
ABEOAbeona Therapeutics2026-07-21 11:30 EST
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
ABEOAbeona Therapeutics2026-05-11 12:30 EST
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
RCKTRocket Pharmaceuticals2026-06-12 11:00 EST
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
PHARPharming Group2026-08-13 05:00 EST
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
RCKTRocket Pharmaceuticals2026-05-28 11:00 EST
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
TSHATaysha Gene Therapies2026-08-03 12:00 EST
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
NTLAIntellia2026-04-27 11:00 EST
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-08-19 12:05 EST
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
Stock data
- Close
- 1.38 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States